What are recommendations for consolidation ovarian cancer treatment?

Updated: Jan 14, 2019
  • Author: Shannon M Grabosch, MD; Chief Editor: from Memorial Sloan-Kettering - Yukio Sonoda, MD  more...
  • Print


Consolidation is treatment given after completion of front-line therapy with a complete clinical or pathologic response.

Bevacizumab appears to improve progression-free survival when used as single-agent therapy for consolidation if it was used in a combination regimen as up-front treatment. However, improvements in overall survival appear to be restricted to high-risk subgroups and are not consistent over studies. [17, 22, 23] Thus, the use of bevacizumab as consolidation therapy remains controversial.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!